Effect of Cognitive-behavior Therapy on Fear Responses to Body Symptoms in Patients With Panic Disorder

Philipps University

Status: Completed

Conditions: Panic Disorder With Agoraphobia; Panic Disorder Without Agoraphobia

Treatments: Behavioral: Cognitive-behavior therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT04568109

PA_CBT_HV

Details and patient eligibility

About

The present study aims to investigate a potential mechanism of successful CBT for panic disorder, i.e., the reduction of excessive anxious apprehension and fear responses to panic-related body symptoms in the context of CBT treatment. In the present non-randomized interventional study, effects of cognitive behavior therapy on reported symptoms and fear responses to panic-related body symptoms are investigated. It is expected that symptom improvement during CBT is associated with a decrease in the activation of the brain's fear network to panic-related body symptoms.

Full description

Changes in fear responses to body symptoms in the course of CBT are investigated in patients with PD by applying a highly standardized hyperventilation task (provoking panic-related body symptoms) prior to and after a manualized CBT or a waiting period. Activation of the brain's fear network (defensive activation) is indexed by the potentiation of the startle eyeblink response.

Enrollment: 58 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• current primary diagnosis of panic disorder (with or without agoraphobia) as defined by the criteria of the diagnostic and statistical manual, fourth revision/text revision (DSM-IV-TR) (determined using the Composite International Diagnostic Interview and verified by a certified psychotherapist)
• age 18 - 65 years

Exclusion criteria

• current suicidal intent
• any psychotic or bipolar disorder
• borderline personality disorder
• a medical condition that could explain patients' symptoms
• physical contradictions regarding application of exposure-based CBT (e.g., neurological disease)
• Patients has to be on a stable psychopharmacological medication schedule prior to study entry for at least 12 weeks
• Intake of benzodiazepines

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

58 participants in 2 patient groups

Exposure-based cognitive-behavior therapy

Experimental group

Description:

Patients are treated in accordance with a manualized protocol (Gloster et al., 2011)

Treatment:

Behavioral: Cognitive-behavior therapy

Wait-List control condition

No Intervention group

Description:

Patients are assessed prior to and after a 12-week waiting period. Patients are treated after this 12-week delay.